This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Ray ME , Levy LB , Horwitz EM , Kupelian PA , Martinez AA , Michalski JM , Pisansky TM , Zelefsky MJ , Zietman AL , Kuban DA
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
Urology. 2006 Dec;68(6) :1257-1262
AbstractObjectives. To determine whether nadir prostate-specific antigen (PSA) levels within 12 months (nadir PSA12) after completion of radiotherapy (RT) can be used as an early marker of recurrence risk. Methods. A total of 4839 patients were treated with RT and without hormonal therapy from 1986 to 1995 for Stage T1-T2 prostate cancer at nine institutions. Of these 4839 patients, 4833, with a median follow-up of 6.3 years, met the criteria for analysis. The study endpoints included freedom from PSA failure, initiation of androgen deprivation, or documented local or distant failure (PSA-DFS); freedom from clinically apparent distant metastasis (DMFS); and overall survival (OS). Results. Patients with a nadir PSA12 of 2.0 ng/mL or less had an 8-year PSA-DFS, DMFS, and OS rate of 55%, 95%, and 73%, respectively, compared with 40%, 88%, and 69%, respectively, for patients with a nadir PSA12 of more than 2.0 ng/mL. Multivariate analysis confirmed that a nadir PSA12 of greater than 2 ng/mL was an independent predictor of PSA-DFS, DMFS, and OS. Classification and regression tree analysis identified the nadir PSA12 levels after RT associated with PSA-DFS, DMFS, and OS. Nadir PSA12, combined with the pretreatment PSA level, identified patients at particularly high risk of distant metastasis. Conclusions. The results of this large, multi-institutional study have demonstrated that nadir PSA12 is predictive of clinical outcomes for patients with localized prostate cancer after RT. A high pretreatment PSA level and high nadir PSA12 will identify patients at particularly high risk who might benefit from early adjuvant therapy.
NotesISI Document Delivery No.: 117JR Times Cited: 0 Cited Reference Count: 24 Cited References: BREIMAN L, 1984, CLASSIFICATION REGRE, P358 CAVANAUGH SX, 2004, CANCER, V101, P96 COX JD, 1997, INT J RADIAT ONCOL, V37, P1035 CRITZ FA, 1996, J CLIN ONCOL, V14, P2893 CRITZ FA, 1997, UROLOGY, V49, P322 CRITZ FA, 1997, UROLOGY, V49, P668 CRITZ FA, 1999, J UROLOGY, V161, P1199 CROOK JM, 1997, CANCER, V79, P328 CROOK JM, 1998, UROLOGY, V51, P566 DEWITT KD, 2003, UROLOGY, V62, P492 HANLON AL, 2002, INT J RADIAT ONCOL, V53, P297 KAMINSKI JM, 2002, INT J RADIAT ONCOL, V52, P888 KESTIN LL, 1999, CANCER, V86, P1557 KUBAN D, 2005, INT J RADIAT ONCOL, V61, P409 KUBAN DA, 2003, INT J RADIAT ONCOL, V57, P915 KUBAN DA, 2005, J UROLOGY, V173, P1871 LEE WR, 1996, J UROLOGY 1, V156, P450 PEREZ CA, 2001, INT J RADIAT ONCOL, V49, P1287 POLLACK A, 2002, INT J RADIAT ONCOL, V54, P677 POLLACK A, 2004, J CLIN ONCOL, V22, P4569 RAY ME, 2006, INT J RADIAT ONCOL, V64, P1140 THAMES H, 2003, INT J RADIAT ONCOL, V57, P929 ZELEFSKY MJ, 2001, J UROLOGY, V166, P876 ZIETMAN AL, 1996, RADIOTHER ONCOL, V40, P159